Therapeutic potential of oxidant mechanisms in Alzheimer’s disease

REFERENCES

• Mayeux R, Sano M. Treatment of Alzheimer's disease. N EngL I Med. 341, 1670–1679 (1999).
   PubMed Web of Science ®Google Scholar
• •Reviews the role of antioxidants in Alzheimer's disease (AD).
   Google Scholar
• Smith MA, Nunomura A, Zhu X, Takeda A, Perry G. Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer's disease. Anti-oxid. Redox Signal. 2,413–420 (2000).
   Google Scholar
• •Focuses on important sources of oxidative stress in AD.
   Google Scholar
• Marlatt M, Lee HG, Perry G, Smith MA, Zhu X. Sources and mechanisms of cytoplasmic oxidative damage in Alzheimer's disease. Acta NeurobioL Exp. 64,81–87 (2004).
   Google Scholar
• Gomez-Ramos A, Smith MA, Perry G, Avila J. Tau phosphorylation and assembly. Acta NeurobioL Exp. (Wars) 64,33–39 (2004).
   PubMed Web of Science ®Google Scholar
• Castellani RJ, Harris PL, Sayre LM et al. Active glycation in neurofibrillary pathology of Alzheimer's disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine. Free Radic. Biol. Med. 31, 175–180 (2001).
   PubMed Web of Science ®Google Scholar
• Liu Q, Raina AK, Smith MA, Sayre LM, Perry G. Hydroxynonenal, toxic carbonyls, and Alzheimer's disease. MoL Aspects Med. 24,305–313 (2003).
   PubMedGoogle Scholar
• •• Reviews important oxidative events in AD.
   Google Scholar
• Nunomura A, Perry G, Pappolla MA et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. Neurosci. 19,1959–1964 (1999).
   Web of Science ®Google Scholar
• •Shows nucleic acid oxidation in AD.
   Google Scholar
• Sayre LM, Perry G, Atwood CS, Smith MA. The role of metals in neurodegenerative diseases. Cell. MoL Biol. 46,731–741 (2000).
   PubMed Web of Science ®Google Scholar
• Hirai K, Aliev G, Nunomura A et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci. 21, 3017–3023 (2001).
   PubMed Web of Science ®Google Scholar
• Castellani R, Hirai K, Aliev G et aL Role of mitochondrial dysfunction in Alzheimer's disease. J Neurosci. Res. 70,357–360 (2002).
   PubMed Web of Science ®Google Scholar
• •Shows that mitochondria is intimately involved in the oxidative stress occurring in AD.
   Google Scholar
• Cash AD, Aliev G, Siedlak SL et al. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am. J PathoL 162, 1623–1627 (2003).
   PubMed Web of Science ®Google Scholar
• Nunomura A, Perry G, Hirai K et al. Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome. Ann. NY Acad. Sci. 893,362–364 (1999).
   PubMed Web of Science ®Google Scholar
• •Discusses nucleic acid oxidation in AD.
   Google Scholar
• Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangelos EG, Kokmen E. Mild cognitive impairment: a possible predictor of Alzheimer's disease. Arch. NeuroL 56, 303–308 (1999).
   PubMed Web of Science ®Google Scholar
• Morris JC, Storandt M, Miller JP et al. Mild cognitive impairment represents early-stage Alzheimer's disease. Arch. NeuroL 58,397–405.
   Google Scholar
• Schmidt R, Hayn M, Reinhart B et al. Plasma antioxidants and cognitive performance in middle-aged and older adults: results of the Austrian stroke prevention study. J Am. Geriatr. Soc. 46, 1407–1410 (1998).
   PubMed Web of Science ®Google Scholar
• Berr C, Balansard B, Arnaud J, Roussel AM, Alperovitch A for the EVA study group: cognitive decline is associated with systemic oxidative stress: the EVA study. I Am. Geriatr. Soc. 48,1285–1291 (2000).
   PubMed Web of Science ®Google Scholar
• Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer's disease. Arch. NeuroL 59, 972–976 (2002).
   PubMedGoogle Scholar
• Rinaldi P, Polidori MC, Metastasio A et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. NeurobioL Aging 24, 915–919 (2003).
   PubMed Web of Science ®Google Scholar
• Atwood CS, Obrenovich ME, Liu T et al. Amyloid-B: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid- p. Brain Res. Rev 43,1–16 (2003).
   PubMed Web of Science ®Google Scholar
• •Reviews the role of amyloid-3 (A13).
   Google Scholar
• Nunomura A, Perry G, Pappola MA et al. Neuronal oxidative stress precedes amyloid-3 deposition in Down's syndrome. I NeuropathoL Exp. NeuroL 59, 1011–1017 (2000).
   Google Scholar
• •Shows that oxidative stress is the earliest event in AD pathophysiology.
   Google Scholar
• Dong J, Atwood CS, Anderson VE et al. Metal binding and oxidation of amyloid-3 within isolated senile plaque cores: raman microscopic evidence. Biochemistry 42, 2768–2773 (2003).
   PubMed Web of Science ®Google Scholar
• Cuajungco MP, Goldstein LE, Nunomura A et al. Evidence that the 3-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of AB by zinc. J Biol. Chem. 275,19439-19442 (2000).
   Google Scholar
• Cadenas E, Davies KJ. Mitochondrial free radical generation, oxidative stress and aging. Free Radic. Biol. Med. 29,222–230 (2000).
   PubMed Web of Science ®Google Scholar
• Varadarajan S, Yatin S, Aksenova M, Butterfield DA. Alzheimer's amyloid 13-peptide-associated free radical oxidative stress and neurotoxicity. I Struct. Biol. 130, 184–208 (2000).
   Google Scholar
• Kontush A, Berndt C, Weber W eta]. Amyloid-P is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic. Biol. Med. 30,119–128 (2001).
   Google Scholar
• Huang X, Atwood CS, Hartshorn MA et al. The AB peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38,7609–7616 (1999).
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Castegna A, Lauderback CM, Drake J. Evidence that amyloid peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. NeurobioL Aging 23,655–664 (2002).
   PubMed Web of Science ®Google Scholar
• Xu J, Chen S, Ahmed SH et aL Amyloid 13- peptides are cytotoxic to oligodendrocytes. Neurosci. 21, RC118 (2001).
   Google Scholar
• Longo VD, Viola KL, Klein WL, Finch CE. Reversible inactivation of superoxide-sensitive aconitase in A 131_42-treated neuronal cell lines. j Neurochem. 75, 1977–1985 (2000).
   PubMed Web of Science ®Google Scholar
• Kontush A. Amyloid-B: an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease. Free Radic. BioL Med. 31,1120–1131 (2001).
   PubMed Web of Science ®Google Scholar
• ••Discusses the role of AP in AD.
   Google Scholar
• Rottkamp CA, Raina AK, Zhu X et al. Redox-active iron mediated amyloid-3 toxicity. Free Radic. BioL Med. 30,447-450 (2001).
   Google Scholar
• Bush Al. Metal complexing agents as therapies for Alzheimer's disease. NeurobioL Aging23, 1031–1038 (2002).
   PubMed Web of Science ®Google Scholar
• Finefrock AE, Bush Al, Doraiswamy PM. Current status of metals as therapeutic targets in Alzheimer's disease. I Am. Geriatr: Soc. 51,1143-1148 (2003).
   Google Scholar
• Ritchie CW, Bush Al, Mackinnon A et aL Metal-protein attenuation with iodochlorhydroxyquin (clioquino0 targeting AB amyloid deposition and toxicity in Alzheimer's disease: a pilot Phase 2 clinical trial. Arch. NeuroL 60, 1685–1691 (2003).
   Google Scholar
• Rosenberg RN. Metal chelation therapy for Alzheimer's disease. Arch. NeuroL 60, 1678–1679 (2003).
   PubMedGoogle Scholar
• Butterfield DA, Bush Al. Alzheimer's amyloid 3-peptide (1-42): involvement of m ethionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. NeurobioL Aging 25,563–568 (2004).
   PubMed Web of Science ®Google Scholar
• Lue LF, Kuo YM, Roher AE et al Soluble amyloid 13 peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. PathoL 155,853–862 (1999).
   Google Scholar
• Buée L, Bussiere T, Buée-Scherrer V, Delacourte A, Hof PR. Tau isoforms in neurodegenerative disorders. Brain Res. Rev 33,95–130 (2000).
   PubMed Web of Science ®Google Scholar
• Sontag E, Nunbhakdi-Craig V, Lee G et al. Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies. I BioL Chem. 274, 25490–25498 (1999).
   Google Scholar
• Hamdane M, Delobel P, Samba A-V et al. Neurofibrillary degeneration of the Alzheimer-type: an alternate pathway to neuronal apoptosis? Biochem. PharmacoL 66,1619–1625 (2003).
   Web of Science ®Google Scholar
• Garcia ML, Cleveland DW. Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. CUIT: Opin. CelL BioL 13,41–48 (2001).
   Google Scholar
• Takeda A, Smith MA, Avila J et aL In Alzheimer's disease, heme oxygenase is coincident with A1z50, an epitope of if induced by 4-hydroxy-2-nonenal modification. j Neurochem. 75, 1234–1241 (2000).
   PubMed Web of Science ®Google Scholar
• •• Focuses on important oxidative markers.
   Google Scholar
• Morsch R, Simon W, Coleman PD. Neurons may live for decades with neurofibrillary tangles. I NeuropathoL Exp. NeuroL 58,188–197 (1999).
   PubMed Web of Science ®Google Scholar
• Wataya T, Nunomura A, Smith MA et al. High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal. j BioL Chem. 277,4644–4648 (2002).
   PubMed Web of Science ®Google Scholar
• Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA. Activation of p38 kinase links if phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer's disease. I NeuropathoL Exp. NeuroL 59,880–888 (2000).
   Google Scholar
• Zhu X, Raina AK, Rottkamp CA et aL Activation and redistribution of the c-Jun N-terminal kinase/stress activated protein kinase in degeneration neurons in Alzheimer's disease. j Neurochem. 76, 435–441 (2001).
   PubMed Web of Science ®Google Scholar
• Zhu X, Rottkamp CA, Hartzler A et al. Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. Neurochem. 79,311–318 (2001).
   PubMed Web of Science ®Google Scholar
• Perry G, Nunomura A, Hirai K et al. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's disease and other neurodegenerative diseases? Free Radic. BioL Med. 33, 1475–1479 (2002).
   Google Scholar
• Schenk D, Barbour R, Dunn W et aL Immunization with amyloid-13 attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400,173–177 (1999).
   PubMed Web of Science ®Google Scholar
• •First paper about A13 clearance in transgenic mice.
   Google Scholar
• Games D, Bard F, Grajeda H et al. Prevention and reduction of AD-type pathology in PDAPP mice immunized with A131_42. Ann NY Acad. Sci. 920,274-284 (2000).
   Google Scholar
• Bacskai BJ, Kajdasz ST, Christie RH et al Imaging of amyloid-13 deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nature Med. 7,369–372 (2001).
   PubMed Web of Science ®Google Scholar
• •Shows in vivo A13 clearance.
   Google Scholar
• Janus C. Vaccines for Alzheimer's disease: how close are we? CNS Drugs 17,457–474 (2003).
   PubMed Web of Science ®Google Scholar
• Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFeria FM. AB immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43,321–332 (2004).
   Google Scholar
• Bard F, Cannon C, Barbour R et aL Peripherally administered antibodies against amyloid 3-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nature Med. 6,916–919 (2000).
   PubMed Web of Science ®Google Scholar
• DeMattos RB, Bales KR, Cummins DJ et al. Peripheral antiAll antibody alters CNS and plasma AB burden in a mouse model of Alzheimer's disease. Proc. NatL Acad. Sci. USA 98,8850–8855 (2001).
   PubMed Web of Science ®Google Scholar
• Monsonego A, Weiner HL. Immunotherapeutic approaches to Alzheimer's disease. Scientv302, 834–838 (2003).
   Google Scholar
• •Reviews immunotherapeutic approaches.
   Google Scholar
• Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer's disease after immunization with amyloid-3 peptide: a case report. Nature Med. 9, 448–452 (2003).
   PubMed Web of Science ®Google Scholar
• •Shows the side effects caused by AP immunotherapy.
   Google Scholar
• Dodel RC, Hampel H, Du Y. Immunotherapy for Alzheimer's disease. Lancet NeuroL 2,215–220 (2003).
   PubMed Web of Science ®Google Scholar
• Josien H. Recent advances in the development of 7-secretase inhibitors. CUIT: Opin. Drug Discov. DeveL 5,513–525 (2002).
   Google Scholar
• •Reviews secretase inhibitors.
   Google Scholar
• Davey HF, John V, Anderson JP et aL Functional 7-secretase inhibitors reduce 13-amyloid peptide levels in brain. Neurochem. 76,173–181 (2001).
   PubMed Web of Science ®Google Scholar
• Das I, Craig C, Funahashi Y et al. Notch oncoproteins depend on y- secretase/presenilin activity for processing and function. j BioL Chem. 279, 30771–30780 (2004).
   PubMed Web of Science ®Google Scholar
• •Shows the adverse side effects caused by secretase inhibitors.
   Google Scholar
• Louvi A, Sisodia SS, Grove EA. Presenilin 1 in migration and morphogenesis in the central nervous system. Development 131, 3093–3105 (2004).
   Google Scholar
• Alves da Costa C, Ayral E, Hernandez JF, St George-Hyslop P, Checler E Presenilin-directed inhibitors of y-secretase trigger caspase 3 activation in presenilin-expressing and presenilin-deficient cells. J. Neurochem. 90,800-806 (2004).
   Google Scholar
• Fukuchi K, Kamino K, Deeb SS, Furlong CE, Sundstrom JA, Smith AC, Martin GM. Expression of a carboxy-terminal region of the 3-amyloid precursor protein in a heterogeneous culture of neuroblastoma cells: evidence for altered processing and selective neurotoxicity. Brain Res. MoL Brain Res. 16,37-46 (1992).
   Google Scholar
• Fukuchi K, Sopher B, Furlong CE, Smith AC, Dang N, Martin GM. Selective neurotoxicity of COOH-terminal fragments of the 3-amyloid precursor protein. Neurosci. Lett. 154,145-148 (1993).
   Google Scholar
• Kim HS, Park CH, Cha SH et al. Carboxyl-terminal fragment of Alzheimer's APP destabilizes calcium homeostasis and renders neuronal cells vulnerable to excitotoxicity. FASEB J 14,1508–1517 (2000).
   PubMed Web of Science ®Google Scholar
• Oster-Granite ML, McPhie DL, Greenan J, Neve RL. Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein. J. Neurosci. 1,6732–6741 (1996).
   Google Scholar
• Arters J, McPhie D, Neve RL, Berger- Sweeny J. Sex-dependent cognitive impairments in transgenic mice that overexpress the carboxy-terminal fragment of the amyloid precursor peptide (APP-C100). Soc. Neurosci. Abst. 21,1483 (1995).
   Google Scholar
• Pratico D, Delanty N. Oxidative injury in disease of the central nervous system: focus on Alzheimer's disease. Am. J Med. 109, 577–585 (2000).
   PubMed Web of Science ®Google Scholar
• Rottkamp CA, Nunomura A, Hirai K, Sayre LM, Perry G, Smith MA. Will antioxidants fulfill their expectations for the treatment of Alzheimer's disease? Mech. Ageing Dev.116, 169–179 (2000).
   PubMed Web of Science ®Google Scholar
• Perry G, Taddeo MA, Nunomura A et al. Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases: beyond damage and response. Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 133,507–513 (2002).
   PubMed Web of Science ®Google Scholar
• •Discusses the positive role (compensatory response) of lesions in AD pathophysiology.
   Google Scholar
• Delanty N, Dichter MA. Antioxidant therapy in neurologic disease. Arch. Neurol. 57,1265–1270 (2000).
   PubMed Web of Science ®Google Scholar
• Sano M. Current concepts in the prevention of Alzheimer's disease. CNS Spectr. 8,846–853 (2003).
   PubMed Web of Science ®Google Scholar
• ••Reviews studies performed with severalantioxidants.
   Google Scholar
• Grundman M. Vitamin E and Alzheimer's disease: the basis for additional clinical trials. Am. J Clin. Nutr. 71, S630—S636 (2000).
   Web of Science ®Google Scholar
• Morris MC, Evans DA, Bienias JL et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer's disease in a biracial community study. JAMA 287, 3230–3237 (2002).
   PubMed Web of Science ®Google Scholar
• Grodstein F, Chen J, Willett WC. High- dose antioxidant supplements and cognitive function in community-dwelling elderly women. Am. J Clin. Nutr. 77,975–984 (2003).
   Google Scholar
• Zandi PP, Anthony JC, Khachaturian AS et al. Reduced risk of Alzheimer's disease in users of antioxidant vitamin supplements: the Cache County Study. Arch. Neurol. 61, 82–88 (2004).
   PubMed Web of Science ®Google Scholar
• •A relevant clinical trial.
   Google Scholar
• Sung S, Yao Y, Uryu K, Yang H, Lee VM, Trojanowski JQ, Pratico D. Early vitamin E supplementation in young but not aged mice reduces AB levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J 18,323–325 (2004).
   Google Scholar
• Stackman RW, Eckenstein F, Frei B, Kulhanek D, Nowlin J, Quinn JE Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Gingko biloba treatment. Exp. Neurol. 184, 510–520 (2003).
   PubMed Web of Science ®Google Scholar
• •Relevant animal study.
   Google Scholar
• Le Bars PL, Kieser M, Itil KZ. A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia. Dement. Geriatr. Cogn. Disord. 11,230-237 (2000).
   Google Scholar
• •Relevant clinical trial.
   Google Scholar
• van Dongen M, van Rossum E, Kessels A, Sielhorst H, Knipschild P Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. I Clin. Epidemiol. 56,367–376 (2003).
   PubMed Web of Science ®Google Scholar
• Hagen TM, Ingersoll RT, Lykkesfeldt J et al. (R)-B-Lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J 13,411–418 (1999).
   PubMed Web of Science ®Google Scholar
• ••Relevant animal study.
   Google Scholar
• Suh JH, Wang H, Liu R-M, Liu J, Hagen TM. (R)-B-Lipoic acid reverses the age-related loss in GSH redox status in postmitotic tissues: evidence for increased cysteine requirement for GSH synthesis. Arch. Biochem. Biophys. 423,126-135 (2004).
   Google Scholar
• Hager K, Marahrens A, Kenklies M, Riederer P, Munch G. B-Lipoic acid as a new treatment option for Alzheimer type dementia. Arch. Gerontol. Geriat. 32, 275–282 (2001).
   Google Scholar
• Fri:inch L, Götz ME, Weinminler M, Youdim MBH, Barth H, Riederer P (R)-, but not (S)-ot lipoic acid stimulates complex in vascular dementia, but not in Alzheimer dementia. J Neural Transm. 111, 295–310 (2004).
   Google Scholar
• Lovell MA, Xie C, Xiang S, Markesbery WR. Protection against amyloid 3-peptide and iron/hydrogen peroxide toxicity by 13-lipoic acid. J Alzheimers Dis. 5,229–239 (2003).
   PubMed Web of Science ®Google Scholar
• Engelhart MJ, Ruitenberg A, Swieten JC, Witteman JCM, Hofman A, Breteler MB. Dietary antioxidants and the risk of dementia. The Rotterdam study. Neurobiol. Aging 21, S203 (2000).
   Google Scholar
• •Relevant epidemiologic trial.
   Google Scholar
• Masaki KH, Losonczy KG, Izmirlian G etal. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 54, 1265–1272 (2000).
   Google Scholar
• •• Relevant epidemiologic trial.
   Google Scholar
• Laurin D, Masaki KH, Foley DJ, White LR, Launer U. Midlife dietary intake of antioxidants and risk of late-life incident dementia: the Honolulu—Asia Aging Study. Am. J. Epidemiol. 159,959-967 (2004).
   Google Scholar
• Perkins AJ, Hendrie HC, Callahan CM etal. Association of antioxidants with memory in a multiethnic elderly sample using the Third National Health and Nutrition Examination Survey. Am. J Epidemiol. 150,37–44 (1999).
   Google Scholar
• Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double-blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int. Clin. Psychopharmacol. 18,61–71 (2003).
   Google Scholar
• •Relevant clinical trial.
   Google Scholar
• Thal LJ, Calvani M, Amato A, Carta A. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. Neurology55,805–810 (2000).
   PubMed Web of Science ®Google Scholar
• Terano T, Fujishiro S, Ban T et al. Docosahexaenoic acid supplementation improves the moderately severe dementia from thrombotic cerebrovascular diseases. Lipids34, S345—S346 (1999).
   Web of Science ®Google Scholar